CTXR · Citius Pharmaceuticals Inc
United States · RS rating 13 · As of 2026-10-14
| Price | 0.47 USD |
|---|---|
| 1-day change | -2.3% |
| RS rating (overall / 1M / 3M / 12M) | 13 / 14 / 34 / 10 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 16 / 19 / 32 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -150.0% |
| Sales growth Q/Q | -57.7% |
| Distance from 52-week high | +74.5% |
| Market cap (USD) | $20.9M |